Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar.

Trial Profile

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Apr 2013

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms PREDICT
  • Sponsors Bayer
  • Most Recent Events

    • 19 Oct 2012 New source identified and integrated (German Clinical Trials Register; DRKS00004113).
    • 13 Sep 2011 Final results will be presented at ECCO-ESMO 2011, according to a Bayer press release.
    • 29 Sep 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top